14Jul
Japan Tightens Foreign Direct Investment Regulations on Life Science Companies - Prior notification requirements under the Japanese regulations were expanded to cover investments in life science companies.
On June 15, 2020, the Japanese government implemented new regulations that designate the manufacture of pharmaceuticals for infectious diseases and the manufacture of highly-controlled medical devices (medical devices that are classified as Class III or Class IV in Japan, such as a heart–lung machines and ventilators) as both "Designated Businesses" and "Core Businesses" under the Foreign Exchange and Foreign Trade Act of Japan ("FEFTA"). The new regulations were adopted in light of the COVID-19...
By:
Jones Day
Related
In today’s technology-driven business world, organizations are more vulnerable than ever to cyberse...
Read More >
There are many ways that companies can cooperate with each other to combat COVID-19 without running ...
Read More >
On August 29, 2019, the National Labor Relations Board (the “Board”) refused to extend the Nationa...
Read More >
As we previously reported, Illinois implemented the Illinois Secure Choice Savings Program (Program)...
Read More >
What is considered compensable travel time pursuant to the Fair Labor Standards Act (“FLSA”) is no...
Read More >
Last week, the Antitrust Division (Division) of the U.S. Department of Justice (Department or DOJ) i...
Read More >